Top Markets
#1 GoPlus Security GoPlus Security +35.65%
#2 Tutorial Tutorial +22.62%
#3 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +18.85%
#4 Status Status +16.07%
#5 Pons Pons +15.31%
#6 SkyAI SkyAI +14.88%
#7 Verus Coin Verus Coin +13.11%
#8 DMT-NAT DMT-NAT +9.38%
#9 Talus Network Talus Network +9.01%
#10 Nillion Nillion +8.92%
Coin of the day
GoPlus Security GoPlus Security
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
Polydex Pharmaceuticals Limited Polydex Pharmaceuticals Limited

Polydex Pharmaceuticals Limited

POLXF
Classifica tra le azioni #33818
Polydex Pharmaceuticals Limited (PPL), a Toronto, Canada-based company, was... Polydex Pharmaceuticals Limited (PPL), a Toronto, Canada-based company, was incorporated in 1979 and initially operated as Polydex Chemicals Limited before adopting its current name in March 1984. PPL specializes in the research, development, manufacturing, and global marketing of biotechnology-derived products for the human pharmaceutical sector. Beyond its human health focus, PPL also produces vital pharmaceutical intermediates for the veterinary industry. Its core product line centers on dextran and its various derivatives. Notable examples include iron dextran, a compound administered to newborn pigs to combat anemia, and dextran sulphate, a specialized chemical derivative crucial for biotechnology applications and the broader pharmaceutical sector. Furthermore, the company is actively developing Ushercell, a high molecular weight cellulose sulphate. This innovative product is designed for topical vaginal use, primarily aimed at preventing the transmission of AIDS and other sexually transmitted diseases, as well as unplanned pregnancies. PPL's portfolio further extends to supplying ferric hydroxide and hydrogenated dextran solutions. Products reach the market through a combination of independent distributors, wholesalers, and direct sales channels to various companies.
Prezzo delle azioni
$1.99
Ultima sincronizzazione: 2023-08-07
Capitalizzazione di mercato
$6.82M
Variazione (1 giorno)
0.30%
Variazione (1 anno)
0.00%
Paese
CA
Scambia Polydex Pharmaceuticals Limited (POLXF)

Categoria

Healthcare
Ricavi di Polydex Pharmaceuticals Limited (POLXF)
Ricavi nel Aug 2026 TTM: 0
Secondo gli ultimi rapporti finanziari di Polydex Pharmaceuticals Limited, i ricavi attuali dell'azienda (TTM) sono pari a 0. Nel 2026, l'azienda ha registrato ricavi di 0 uguale a i ricavi dell'anno 2026, che erano pari a 0. I ricavi rappresentano l'importo totale generato dalla vendita di beni o servizi. A differenza degli utili, le spese non vengono detratte.
Storico dei ricavi per Polydex Pharmaceuticals Limited da 2026 a 2026
Ricavi alla fine di ogni anno
Anno Ricavi Cambia
Non abbastanza dati per le date fornite.
Ricavi di aziende simili o concorrenti
Azienda Ricavi Differenza nei ricavi Il paese
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $10.11B -
BE